Gender as a key factor of delay in prescribing the first biologic or targeted synthetic drug in patients with rheumatoid arthritis. Data from BIOBADASER 3.0 registry
04/09/2024
Paloma Vela Casasempere* 1 2 3 Lucía Otero-Varela 4 Silvia Gomez-Sabater 2 Rocio Caño-Alameda 2 Cristina Campos Fernández 5 Jerusalem Calvo Gutierrez 6 Yanira Perez-Vera 7 Sara Manrique Arija 8 Sagrario Bustabad 9 Francisco Javier Manero Ruiz 10 Dolores Ruiz-Montesinos 11 Lucía Ruiz 12 Antonio Mera Varela 13 Manuel Moreno 14 Fernando Sánchez-Alonso 4 Isabel Castrejon 15
EULAR 2024
DOI: 10.1136/annrheumdis-2024-eular.3346
https://ard.bmj.com/content/83/Suppl_1/600.1